bfw and Bear.

I'm not a scientist but it strikes me that this is a situation in which (perhaps) statistical significance at the 95% confidence level via a massive sample size was the goal i.e. the absolute changes required a hudge sample. Perhaps even the RRR is impressive but I am sensing the the absolute risk redcution might be quite small. Combine a low absolute risk reduction with a high cost of treatment and it may not attract payers. I haven't seen the numbers so I am just guessing.

As I recall BoM is an event based trial with an expected sample of 2500, each patient to be dosed at least a year. That is a much smaller sample than Merck's 30,000. I am hoping that BoM yields absolute risk reductions like we saw in the post hoc analysis and the were very large as I recall based on the 5 point MACE criteria.

Oh well, there is lot's of room in this unmet needs space in MACE.

GLTA

Toinv